Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: A system and method are provided for safe arming a flying machine that carries an explosive device. Once armed, the flying machine can provide air defense against a target (e.g., an unwanted aircraft) by using the explosive device to kinetically intercept the unwanted aircraft. The flying machine can include an explosive device, an arming device, and one or more sensors (e.g., a 9-axis inertial measurement unit). By processing the sensor data, the flying machine determines whether arming criteria have been satisfied (e.g., the flying machine has attained a desired altitude or undergone a specified pattern of accelerations), and when the arming criteria are satisfied the flying machine arms the explosive device by completing a detonation path. If the explosive device is not detonated, the system returns to a safe state before the flying machine back to its origin.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: A hinge includes a hinge body, a self-close mechanism disposed within the hinge body, and a slow-close mechanism disposed within the hinge body. The hinge body has a first portion rotatable with respect to a second portion between an open position and a closed position. The self-close mechanism applies a closing force on the first portion from an opened angle of rotation between the first portion and the second portion to the closed position having a 0° angle of rotation between the first portion and the second portion. The closing force urges the first portion to the closed position. The slow-close mechanism applies a damping force on the first portion from the opened angle of rotation between the first portion and the second portion to the closed position. The damping force slows a rotational speed of the first portion to the closed position.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: A hinge includes a hinge body, a self-close mechanism disposed within the hinge body, and a slow-close mechanism disposed within the hinge body. The hinge body has a first portion and a second portion, the first portion is rotatable with respect to the second portion between an open position and a closed position. The self-close mechanism applies a closing force on the first portion from a first angle of rotation between the first portion and the second portion to the closed position, the closing force urging the first portion to the closed position. The slow-close mechanism applies a damping force on the first portion from a second angle of rotation between the first portion and the second portion to the closed position, the damping force slowing a rotational speed of the first portion to the closed position.

Abstract: A junction box for electrical wiring includes a housing and a base plate. The housing is adapted to removably connect with the base plate to house the electrical connection. The base plate is secured to a support beam to provide stability to the junction box. The housing and the base plate are either of a unitary structure, or include tabs and/or attachment flanges that provide additional access and stability to the electrical connection, while reducing strain. The junction box may be secured to the support beam via a telescoping bar hanger.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: A junction box for electrical wiring includes a housing and a base plate. The housing is adapted to removably connect with the base plate to house the electrical connection. The base plate is secured to a support beam to provide stability to the junction box. The housing and the base plate are either of a unitary structure, or include tabs and/or attachment flanges that provide additional access and stability to the electrical connection, while reducing strain. The junction box may be secured to the support beam via a telescoping bar hanger.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Systems and methods for the distribution of data center power are disclosed. In one embodiment, the method includes supplying power to a critical load using a stored energy device in response to detecting an outage of a utility; transmitting an on bypass request to a reserve power system via an automatic bypass input upon determining that a capacity of the stored energy device has reached a pre-determined threshold, wherein the on bypass request is transmitted from the primary UPS to a switchboard of the reserve power system; transferring the critical load to the reserve power system if the reserve power system is able to support the critical load, the transferring the critical load to the reserve power system comprising coupling the critical load to the switchboard via an automatic bypass input of the primary UPS.